

1FW 3762

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Katzman et al.
Serial No.:	10/549,488
Filed:	September 15, 2005
Entitled:	Modafinil-Based Neurorehabilitation of Impaired Neurological Function Associated with Brain Injury

Art Unit: 3762

Examiner: (not yet assigned)

Attorney Docket No.: NEU-102.1P US

**Mail Stop AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Sir:

Transmitted herewith are: [X] an Information Disclosure Statement (IDS) under 37 CFR §§ 1.56, 1.97 and 1.98 (3 pages); [X] Form PTO-1449 Information Disclosure Statement (1 page); [X] photocopies of the disclosed documents, to be filed in the above-identified patent application; and [X] a return receipt post card.

**PAYMENT OF FEES**

- [ ] A check in the amount of \$\_\_\_\_\_ (check no. \_\_\_\_\_) in payment of the fee for submission of an information disclosure statement transmitted herewith.
- [X] The Commissioner is hereby authorized to charge payment of any additional fees required under 37 CFR §§ 1.16 or 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0268. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

*Thomas R. Berka*

Thomas R. Berka, Ph.D., Reg. No. 39,606

Leon R. Yankwich, Reg. No. 30,237

Attorneys for Applicants

YANKWICH & ASSOCIATES, P.C.

201 Broadway

Cambridge, Massachusetts 02139

telephone: (617) 374-3700

telefax: (617) 374-0055

**CERTIFICATE OF MAILING**

The undersigned hereby certifies that this correspondence and accompanying documents are being deposited with the U.S. Postal Service as First Class Mail, postage prepaid, in an envelope addressed to **Mail Stop AMENDMENT**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

September 21, 2006

Date



Nasim G. Memon


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Katzman et al.

Serial No.: 10/549,488

Filed: September 15, 2005

Entitled: Modafinil-Based  
Neurorehabilitation of Impaired  
Neurological Function  
Associated with Brain Injury



Art Unit: 3762

Examiner: (not yet assigned)

Attorney Docket No.: NEU-102.1P US

**Mail Stop AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98**

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.97 and 1.98 in the above-identified patent application for consideration by the Patent Office.

A modified Form PTO-1449 listing the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents. This Statement is being submitted before the first Office Action on the merits pursuant to 37 C.F.R. § 1.97(b)(3). Accordingly, no fee is required with this submission.

**U.S. Patent Documents**

U.S. Patent No. 4,177,290 issued December 4, 1979, Lafon;

U.S. Patent No. 4,927,855 issued May 22, 1990, Lafon;

U.S. Patent No. 5,612,379 issued March 18, 1997, Laurent;

U.S. Patent No. US RE37,516 E issued January 15, 2002, Grebow et al.;

U.S. Patent No. US 6,463,328 B1 issued October 8, 2002, John;

U.S. Patent No. US 6,489,363 B2 issued December 3, 2002, Jacobs et al.;  
U.S. Pub. No. US 2002/0098240 A1 published July 25, 2002, Jacobs et al.;  
U.S. Pub. No. US 2003/0022940 A1 published January 30, 2003, Corvari et al.;  
U.S. Pub. No. US 2003/0125391 A1 published July 3, 2003, Jacobs et al.;  
U.S. Pub. No. US 2004/0048931 A1 published March 11, 2004, Heacock et al.;  
U.S. Pub. No. US 2004/0105891 A1 published June 3, 2004, Bentolila et al.; and  
U.S. Pub. No. US 2004/0116532 A1 published June 17, 2004, Heacock et al.

**Other Documents**

Bastuji et al., *Prog. Neuro-Psychopharmacol. & Biol. Psychiat.*, 12: 695-700 (1988)  
Cass et al., *Journal of Pharmaceutical and Biomedical Analysis*, 26: 123-130 (2001);  
Donovan et al., *Therapeutic Drug Monitoring*, 25: 197-202 (2003);  
Duteil et al., *European Journal of Pharmacology*, 180: 49-58 (1990);  
In et al., *Chem. Pharm. Bull.*, 52: 1186-1189 (2004);  
Physician's Desk Reference, 58th ed. (Thomson PDR, Montvale, NJ) pages 1160-1163 (2004);  
Rappaport et al., *Arch. Phys. Med. Rehabil.*, 63: 118-123 (1982);  
Saletu et al., *Int. J. Clin. Pharm. Res.*, 9: 183-195 (1989);  
Walker et al., *Neuron*, 44: 121-133 (2004);  
Wisor et al., *The Journal of Neuroscience*, 21: 1787-1794 (2001);  
Wong et al., *Journal of Clinical Pharmacology*, 39: 30-40 (1999); and  
Wong et al., *Journal of Clinical Pharmacology*, 39: 281-288 (1999).

Applicants do not intend to represent that any of the documents submitted herein is material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicants respectfully request that the documents submitted herein be considered and made of record in this application and that the documents be printed on any patent issuing from this application.

Respectfully submitted,



Thomas R. Berka, Ph.D., Reg. No. 39,606  
Leon R. Yankwich, Reg. No. 30,237  
Attorneys for Applicants  
YANKWICH & ASSOCIATES, P.C.  
201 Broadway  
Cambridge, Massachusetts 02139  
telephone: (617) 374-3700  
telefax: (617) 374-0055

CERTIFICATE OF MAILING


The undersigned hereby certifies that this correspondence and accompanying documents are being deposited with the United States Postal Service, as First Class Mail postage prepaid, in an envelope addressed to **Mail Stop AMENDMENT**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

September 21, 2006

Date



Nasim G. Memon



<b>Modified FORM PTO-1449</b>		<b>ATTY. DOCKET NO.</b> NEU-102.1P US	<b>SERIAL NO.</b> 10/549,488
<b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>		<b>APPLICANT</b> KATZMAN et al.	
(Use several sheets if necessary)		<b>FILING DATE</b> September 15, 2002	<b>GROUP</b> not yet assigned

#### REFERENCE DESIGNATION

#### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	U.S. 4,177,290	12/4/79	Lafon			3/9/1978
	AB	U.S. 4,927,855	5/22/90	Lafon			1/28/1987
	AC	U.S. 5,612,379	3/18/97	Laurent			4/30/1996
	AD	U.S. RE37,516 E.	1/15/02	Grebrow et al.			4/1/1999
	AE	U.S. 6,463,328 B1	10/8/02	John			1/10/2000
	AF	U.S. 6,489,363 B2	12/3/02	Jacobs et al.			10/10/2001
	AG	U.S. 2002/0098240 A1	7/25/02	Jacobs et al.			10/11/2001
	AH	U.S. 2003/0022940 A1	1/30/03	Corvari et al.			5/23/2002
	AI	U.S. 2003/0125391 A1	7/3/03	Jacobs et al.			11/1/2002
	AJ	U.S. 2004/0048931 A1	3/11/04	Heacock et al.			7/10/2003
	AK	U.S. 2004/0105891 A1	6/3/04	Bentolila et al.			11/24/2003
	AL	U.S. 2004/0116532 A1	6/17/04	Heacock et al.			9/11/2003

#### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	TRANSLATION YES NO
	BA						

#### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	CA	Bastuji et al., <i>Prog. Neuro-Psychopharmacol. &amp; Biol. Psychiat.</i> , 12:695-700 (1988)
	CB	Cass et al., <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 26:123-130 (2001)
	CC	Donovan et al., <i>Therapeutic Drug Monitoring</i> , 25:197-202 (2003)
	CD	Duteil et al., <i>European Journal of Pharmacology</i> , 180:49-58 (1990)
	CE	In et al., <i>Chem. Pharm. Bull.</i> , 52:1186-1189 (2004)
	CF	Physician's Desk Reference, 58th ed. (Thomson PDR, Montvale, NJ) pages 1160-1163 (2004)
	CG	Rappaport et al., <i>Arch. Phys. Med. Rehabil.</i> , 63:118-123 (1982)
	CH	Saletu et al., <i>Int. J. Clin. Pharm. Res.</i> , 9:183-195 (1989)
	CI	Walker et al., <i>Neuron</i> , 44:121-133 (2004)
	CJ	Wisor et al., <i>The Journal of Neuroscience</i> , 21:1787-1794 (2001)
	CK	Wong et al., <i>Journal of Clinical Pharmacology</i> , 39:30-40 (1999)
	CL	Wong et al., <i>Journal of Clinical Pharmacology</i> , 39:281-288 (1999)
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

sheet 1 of 1